Evaluation of Xiaoaiping Combined with Oxaliplatin and Capecitabine in the Treatment of Advanced Metastatic Gastric Adenocarcinoma

Objectives: To evaluate the effect of Xiaoaiping combined with oxaliplatin and capecitabine in the treatment of advanced metastatic gastric adenocarcinoma. Methods: Seventy patients with advanced metastatic gastric adenocarcinoma in our hospital from January 2018 to March 2019 were randomly divided into the control group treated with oxaliplatin and capecitabine chemotherapy and the observation group treated with Xiaoaiping. Each group has 35 cases. The short-term efficacy of the two groups was compared. Results: The total effective rate and disease control rate of the observation group were higher than that of the control group. After treatment, tumor markers, vascular endothelial growth factors and inflammatory cytokines were lower than those in the control group. The quality of life score and peripheral lymphocyte subgroup were higher than the control group. The difference was statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusions: Xiaoaiping combined with oxaliplatin and capecitabine is effective in the treatment of advanced metastatic gastric adenocarcinoma. It's worth popularizing.